Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) (DOXYVAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04597424
Recruitment Status : Recruiting
First Posted : October 22, 2020
Last Update Posted : March 17, 2021
Sponsor:
Information provided by (Responsible Party):
ANRS, Emerging Infectious Diseases

Brief Summary:
The study ANRS 174 Doxyvac is a clinical trial that will use Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men and using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) and vaccination with Bexsero.

Condition or disease Intervention/treatment Phase
Unsafe Sex Risk-Taking Drug: Experimental: doxycycline Biological: Bexsero® vaccine Phase 3

Detailed Description:

This is a randomized study with a factorial design for the 2 biomedical interventions (interventions 1 and 2).

Subjects will be randomized and assigned to two different interventions:

  • Intervention 1: PEP with doxycycline or no PEP. Subjects will be randomized 2/1 to receive doxycycline PEP or no PEP
  • Intervention 2: Meningococcal B vaccine (Bexsero®) or no vaccine Subjects will be randomized 1/1 to received 2 doses of Bexsero® vaccine (at the first visit and two months later) or no vaccine

Participants will be randomized in one of the following arms:

  • Arm 1: doxycycline and Bexsero® vaccine (240 participants)
  • Arm 2: doxycycline and no Bexsero® vaccine (240 participants)
  • Arm 3: no doxycycline and Bexsero® vaccine (120 participants)
  • Arm 4: no doxycycline and no Bexsero® vaccine (120 participants)

Randomization will be stratified by whether or not the participant enters in the ancillary study "intestinal microbiota".

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 720 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Arm 1 : doxycycline and Bexsero vaccine Arm 2 : doxycycline and no vaccine Arm 3 : No doxycycline and Bexsero vaccine Arm 3 : No doxycycline and No Bexsero vaccine
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)
Actual Study Start Date : January 19, 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Experimental: doxycycline and Bexsero® vaccine
-doxycycline will be taken by participants as PEP (prophylaxy post exposition) and participants will received Meningococcal B vaccine (Bexsero®) at D0 and M2
Drug: Experimental: doxycycline

2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.

If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.


Biological: Bexsero® vaccine
1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.

Experimental: doxycycline
-doxycycline will be taken by participants as PEP (prophylaxy post exposition)
Drug: Experimental: doxycycline

2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.

If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.


Experimental: Bexsero® vaccine
-Meningococcal B vaccine (Bexsero®) at D0 and M2
Biological: Bexsero® vaccine
1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.

No Intervention: No treatment
-no doxycycline and no Bexsero® vaccine



Primary Outcome Measures :
  1. For intervention 1 (with or without doxycycline PEP) : 1st occurence of chlamydia or syphilis after the enrolment visit (Day 0) [ Time Frame: Month 24 ]

    Intervention 1 (with or without doxycycline PEP) is the first episode of chlamydia or syphilis after the enrolment visit (Day 0) (chlamydia and syphilis diagnosed at the enrolment visit will not be included in the primary endpoint).

    Chlamydia détection will be performed by polymerase chain reaction.Syphilis détection will be performed by antigen.


  2. For intervention 2 with or without Bexsero® vaccine : 1st occurence of gonorrhea reported one month after the second vaccine injection [ Time Frame: Month 24 ]

    Intervention 2 (with or without Bexsero® vaccine) is the first episode of gonorrhea reported one month after the second vaccine injection, so starting at the month 3 visit (gonorrhea episodes diagnosed at the enrolment visit and before the month 3 visit will not be included in the primary endpoint).

    In these analyses, subject follow-up will be right-censored at the time of the first STI.

    Gonorrhea détection will be performed by polymerase chain reaction.



Secondary Outcome Measures :
  1. - Occurrence of a first episode of each of the bacterial STIs as well as cumulative incidence of each bacterial STIs [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]

    - Occurrence of a first episode of each of the bacterial STIs as well as cumulative incidence of each bacterial STIs (syphilis, chlamydia; gonorrhoea and Mycoplasma genitalium) during the trial. In that case, the entire follow-up will be considered.

    Chlamydia détection will be performed by polymerase chain reaction. Syphilis détection will be performed by antigen.

    Mycoplasma genitalium be performed by polymerase chain reaction. Gonorrhea détection will be performed by polymerase chain reaction.


  2. - Occurrence of a new episode of anal or urinary gonorrhoea. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    - Occurrence of a new episode of anal or urinary gonorrhoea. Gonorrhea détection will be performed by polymerase chain reaction.

  3. - Occurrence of a first symptomatic episode of chlamydia infection or gonorrhea [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]

    - Occurrence of a first symptomatic episode of chlamydia infection or gonorrhea at urinary or anal sites.

    Chlamydia détection will be performed by polymerase chain reaction. Gonorrhea détection will be performed by polymerase chain reaction.


  4. - Proportion of patient with Methicillin-Resistant Staphylococcus Aureus and/or doxycycline resistant Staphylococcus aureus from throat. Fecal carriage of Extended-Spectrum Beta-Lactamase-producing Enterobacteriaceae Composition of intestinal microbiota [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    detection from throat swab of carriage of MRSA (methicillin-resistant Staphylococcus aureus) and/or doxycycline resistant Staphylococcus aureus, fecal carriage of ESBL (extended-spectrum beta-lactamase) -producing Enterobacteriaceae, and composition of the intestinal microbiota), all détected by polymerase chain reaction assay

  5. - Incidence of clinical and biological adverse events [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    Proportion of patients experiencing a clinical or biological adverse events (ANRS scale)

  6. - Proportion of patients taking doxycycline [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    Adherence will be evaluated by doxycycline pills taken by patients

  7. - Concentration of doxycycline in hair [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    Adherence will be evaluated by détection of doxycyclin in hair

  8. - Proportion of patients with Antibiotic susceptibilities of all strains of NG (Neisseria gonorrhoeae), CT (chlamydiae trachomatis), MG (mycoplasma genitalium) [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    identification of Antibiotic susceptibilities of all strains of NG (Neisseria gonorrhoeae), CT (chlamydiae trachomatis), MG (mycoplasma genitalium) to doxycycline, macrolides, fluoroquinolones and third generation cephalosporin will be performed by PCR (polymerase chain reaction assay)

  9. - Rate of cured STIs after treatment with or without PEP. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    declaration of illnesses from infection to healing

  10. - Incidence of resistance to antibiotics of Neisseria gonorrhoeae with or without doxycycline. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    Proportion of participants with resistance to antibiotics of Neisseria gonorrhoeae will be evaluated by polymerase chain reaction to detect mutations

  11. - Incidence of Serum bactericidal activity against meningococcal and gonococcal antigens over time in participants of Bexsero®'s arm. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    Proportion of participants with Serum bactericidal activity against meningococcal and gonococcal antigens

  12. - Incidence of clinical and biological adverse events following Bexsero® vaccine. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    Proportion of participants experiencing a clinical and biological adverse events following Bexsero® vaccine (ANRS scale)

  13. - Prevalence and incidence of meningococcal carriage in pharyngeal, anal and urine swabs. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    detection of meningococcal carriage in pharyngeal, anal and urine swabs will be performed

  14. - Impact of PEP or Bexsero® vaccine on sexual behaviour [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    rates of condom use for receptive anal intercourse, number of sexual partners and number of sex acts over time

  15. - Incidence of HIV infection with both prophylaxis strategies. [ Time Frame: Month 2, Month 3, Month 6, Month 12, Month 18, Month 21, Month 24 ]
    HIV infection will be tested by serology and western blot assay



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Mens who have sex with mens (MSM) enrolled in the ANRS PREVENIR study.
  • At least 6-month experience with PrEP (within the ANRS PREVENIR study or before starting the ANRS PREVENIR study).
  • No clinical manifestation of primary HIV infection and no symptom of bacterial STI (chlamydia, gonorrhea, M. genitalium or syphilis).
  • History of documented bacterial STI with at least one episode in the last 12 months.
  • Participants who agree to sign the information and consent form specific to this study.
  • Valid health insurance (State medical aid (AME) is not health insurance).

Exclusion Criteria:

  • Syphilis diagnosed prior to inclusion without serologic evidence of cure (cure is defined as decreased by at least 4-fold of the non-treponemal antibody titer [Venereal Disease Research Laboratory (VDRL), Rapid Plasma Reagin (RPR)] relative to the titer at initiation of treatment of syphilis).
  • HIV infection.
  • Previous vaccination with Bexsero® or any other meningococcal B vaccine.
  • Vaccination during the 4 weeks (28 days) preceding the first vaccination of the study.
  • Previous vaccination with an experimental vaccine in the previous 5 years.
  • Systemic treatment with retinoids : isotretinoin (Acnetrait®, Procuta®, Curacné®, Contracné®, …).
  • Treatment with enzyme-inducing anticonvulsants (carbamazepine, phenobarbital, phenytoin, ….).
  • Participant who has received immunoglobulins, a transfusion of blood or blood derivatives in the last 3 months.
  • Known or suspected congenital or acquired immunodeficiency; immunosuppressive treatment in the last 6 months, such as cancer chemotherapy or radiotherapy; long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks in the last 3 months)
  • Known allergy to antibiotics of the tetracycline family.
  • Known allergy to any component of the Bexsero® vaccine.
  • Known allergy to any component of the doxycycline pill.
  • Known allergy to latex (contained in the vaccine cap).
  • Thrombocytopenia or any other known coagulation disorder, which would be a contraindication to an intramuscular injection of Bexsero® vaccine.
  • Documented oesophageal lesion
  • Acute respiratory infection or severe acute febrile illness or systemic reaction that may present a significant risk if vaccinated in the month prior to inclusion.
  • Any condition (clinical) that, in the investigator's opinion, would contraindicate intramuscular vaccination and blood sampling.
  • Oral Anticoagulant treatment.
  • Continuous treatment with doxycycline at inclusion.
  • Vitamin A treatment in case of intake of 10 000 international unit or more.
  • Participation in another research including an exclusion period still in progress at the time of inclusion.
  • Under guardianship or curator, or deprived of liberty by a judicial or administrative decision.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04597424


Contacts
Layout table for location contacts
Contact: Jean-Michel MOLINA, MD +33142499066 jean-michel.molina@aphp.fr
Contact: Jade GHOSN, MD +33140257803 jade.ghosn@aphp.fr

Locations
Layout table for location information
France
Hôpital Bichat Not yet recruiting
Paris, France, 75000
Contact: Jade Ghosn, Dr       jade.ghosn@aphp.fr   
Contact    +33140257803      
Principal Investigator: Jade Ghosn, MD         
Hôpital Hôtel Dieu Recruiting
Paris, France, 75181
Contact: Jean-Paul Viard, MD         
Principal Investigator: Jean-Paul Viard, MD         
Hôpital Saint-Louis Recruiting
Paris, France, 75475
Contact: Jean-Michel Molina, MD         
Principal Investigator: Jean-Michel Molina, Pr         
Hôpital Saint-Antoine Recruiting
Paris, France, 75571
Contact: Karine Lacombe, MD         
Principal Investigator: Karine Lacombe, Pr         
Hôpital pitié Salpetrière Recruiting
Paris, France, 75651
Contact: Christine Katlama, Pr       christine.katlama@psl.aphp.fr   
Principal Investigator: Christine Katlama, Pr         
Hôpital Pitié-Salpétrière Recruiting
Paris, France, 75651
Contact: Anne Simon, MD         
Principal Investigator: Anne Simon, MD         
Hôpital Necker-Enfants Malades Recruiting
Paris, France, 75743
Contact: Claudine Duvivier, MD         
Principal Investigator: Claudine Duvivier, MD         
Hôpital Européen Georges Pompidou Recruiting
Paris, France, 75908
Contact: Juliette Pavie, MD         
Principal Investigator: Juliette Pavie, MD         
Hôpital Tenon Recruiting
Paris, France, 75970
Contact: Gilles Pialoux, MD         
Principal Investigator: Gilles Pialoux, Pr         
Sponsors and Collaborators
ANRS, Emerging Infectious Diseases
Layout table for additonal information
Responsible Party: ANRS, Emerging Infectious Diseases
ClinicalTrials.gov Identifier: NCT04597424    
Other Study ID Numbers: ANRS 174 DOXYVAC
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ANRS, Emerging Infectious Diseases:
STI infection
PREVENTION
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Sexually Transmitted Diseases
Virus Diseases
Doxycycline
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents